Black Diamond joins ArriVent in the PACC pack
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.